IMPORTANT SAFETY INFORMATION

Contraindications
Do not use Gleolan in patients with:
• Hypersensitivity to aminolevulinic acid (ALA) or porphyrins
• Acute or chronic types of porphyria

Warnings and Precautions
Due to the risk of phototoxic reactions, do not administer phototoxic drugs and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

Please see full Important Safety Information on page 7 and full Prescribing Information in pocket.
EOR Is Associated With Improved Outcomes in Patients With Primary and Recurrent Glioma

The better you can demarcate the tumor/brain interfaces, the better you can make optimal resection decisions during surgery.

EOR, extent of resection.
 Illuminate With Gleolan—the First and Only FDA-Approved Optical Imaging Agent That Enhances Visualization of Malignant Tissue for a More Complete Resection¹

**GLEOLAN® (aminolevulinic acid HCl) DEMONSTRATED SIGNIFICANT IMPROVEMENT IN EOR VS WHITE LIGHT¹⁶,⁷**

- 64% of Gleolan patients had “completeness” of resection vs 38% in the control arm ($P<0.0001$)¹⁶,⁷
- Surgical guidance with Gleolan is not limited by brain shift⁸
- Gleolan may be used in suspected HGG patients of any age¹

In a clinical study, patients with suspected malignant glioma amenable to complete resection of contrast-enhancing tumor were randomly assigned to 20 mg/kg Gleolan for fluorescence-guided resection (n=176) or to conventional microsurgery with white light (n=173). A primary endpoint was the number of patients without contrast-enhancing tumor on early MRI (within 72 hours after surgery for resection)⁹

Gleolan helps you delineate between malignant and normal brain tissue to maximize a safe resection⁹

**IMPORTANT SAFETY INFORMATION (continued)**

**Warnings and Precautions (continued)**

Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

Please see full Important Safety Information on page 7 and full Prescribing Information in pocket.
Direct, Real-Time Visualization With Gleolan Allows You to Assess and Resect the Margins of Malignant Tissue More Precisely

Gleolan® (aminolevulinic acid HCl) achieved >95% positive predictive value (PPV) for identification of malignant tissue across all studies

PPV AND NPV ACROSS 3 PIVOTAL STUDIES

<table>
<thead>
<tr>
<th>MEASURE</th>
<th>STUDY 1(^1,6,10) PRIMARY (N=297)*</th>
<th>STUDY 2(^1,6,11) RECURRENT (N=370)*</th>
<th>STUDY 3(^1,6) PRIMARY (N=479)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPV</td>
<td>96.2</td>
<td>96.6</td>
<td>97.8</td>
</tr>
<tr>
<td>NPV</td>
<td>24.1</td>
<td>18.8</td>
<td>18.8</td>
</tr>
</tbody>
</table>

\*N=number of total (fluorescent and non-fluorescent) biopsies

- Gleolan fluorescence in invasive glioblastomas is linearly correlated with Gd-enhanced magnetic resonance image contrast but demonstrates a higher diagnostic accuracy

NPV, negative predictive value; Gd, gadolinium.

SEE THE DIFFERENCE WITH GLEOLAN

Fluorescence may also be seen in areas of inflammation or metastases from other tumor types. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. There is a risk of misinterpretation, and errors may occur with use of Gleolan including false negatives and false positives. Administering Gleolan 2-4 hours prior to anesthesia can reduce false negatives. Gleolan must be used with a standard surgical operating microscope adapted with a blue light–emitting light source and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelengths of 375 to 440 nm and for observation from 620 to 710 nm.

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions (continued)

Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

Adverse Reactions

Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting.
PFS With Gleolan by Early Postoperative MRI Resection Status

PFS by early postoperative MRI resection status

- 349 patients aged 23 to 73 years with suspected malignant glioma underwent resection of contrast-enhanced tumor
- Patients were stratified on the basis of completeness of resection (n=177 in the complete resection group; n=167 in the incomplete resection group)
- One of the primary endpoints was 6-month PFS as assessed by MRI; 9-, 12-, 15-, and 18-month PFS were designated as secondary endpoints

Number at Risk, (Censored)

<table>
<thead>
<tr>
<th>Re section Status</th>
<th>Complete</th>
<th>Incomplete</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>177(0)</td>
<td>167(3)</td>
</tr>
<tr>
<td>3.0</td>
<td>128(0)</td>
<td>109(0)</td>
</tr>
<tr>
<td>6.0</td>
<td>71(0)</td>
<td>31(0)</td>
</tr>
<tr>
<td>12.0</td>
<td>26(3)</td>
<td>0(0)</td>
</tr>
<tr>
<td>18.0</td>
<td>7(3)</td>
<td>0(0)</td>
</tr>
<tr>
<td>24.0</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
</tbody>
</table>

PFS, progression-free survival.

Adverse Reactions (continued)

Nervous system disorders occurred in 29% of patients within the first week after surgery and events occurring in >1% of patients included: aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in <1% of patients in the first 6 weeks after surgery.

Please see full Important Safety Information on page 7 and full Prescribing Information in pocket.
Gleolan® (aminolevulinic acid HCl)—supported by data from 5 open-label clinical trials on 527 patients

• Adverse reactions occurring in >1% of patients the week following surgery were pyrexia, hypotension, nausea, and vomiting

Recognized in guidelines for the management of glioma, including:

- American Association of Neurological Surgeons and Congress of Neurological Surgeons (AANS/CNS) Joint Section on Tumors guidelines
- National Comprehensive Cancer Network (NCCN) guidelines (version 2) on central nervous system cancers
- European Society for Medical Oncology (ESMO)

5-ALA has been used in more than 100,000 PATIENTS IN OVER 42 COUNTRIES

Gleolan is easy to administer with oral dosing taken 3 hours (range: 2 to 4 hours) before anesthesia

The recommended reconstituted oral dose of Gleolan is 20 mg/kg
Contraindications
Do not use Gleolan in patients with:
• Hypersensitivity to aminolevulinic acid (ALA) or porphyrins
• Acute or chronic types of porphyria

Warnings and Precautions
Due to the risk of phototoxic reactions, do not administer phototoxic drugs and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

Adverse Reactions
Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting.

Nervous system disorders occurred in 29% of patients within the first week after surgery and events occurring in >1% of patients included: aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in <1% of patients in the first 6 weeks after surgery. In a randomized clinical trial, the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to ALA fluorescence arm compared to the control arm. An imbalance was notable for the adverse events aphasia, ataxia, convulsion and hemianopsia and is likely related to the higher amount of brain resection performed in the ALA arm. At longer follow-up periods, the numbers between the two arms appeared similar.

Worsening of >2 Common Toxicity Criteria grades in alanine aminotransferase and gamma-glutamyl transferase occurred in 15.8% and 11.6% of patients, respectively, within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal for each parameter. At 6 weeks, these measurements remained elevated in 2.9% and 7.5% of patients, respectively. There were no cases of liver failure.

Drug-Drug Interactions
See information under Warnings and Precautions regarding phototoxic reactions.

Please see full Important Safety Information above and full Prescribing Information in pocket.
ILLUMINATE WITH GLEOLAN

The First and Only FDA-Approved Optical Imaging Agent That Enhances Visualization of Malignant Tissue for a More Complete Resection

- 64% of Gleolan® (aminolevulinic acid HCl) patients had completeness of resection vs 38% of patients in the white light control arm (P<0.0001)\(^1,6,7\)
- Low incidence of adverse reactions\(^1\)
  - Adverse reactions occurring in >1% of patients the week following surgery were pyrexia, hypotension, nausea, and vomiting
- Easy-to-administer oral dosing 2-4 hours before anesthesia\(^1\)
- Recognized in AANS/CNS, NCCN, and ESMO guidelines for the treatment of glioma\(^14-16\)

Gleolan should only be used by neurosurgeons who have completed the Gleolan Neurosurgeon Training Program on the use of fluorescence in surgery and passed the exam.

Access the Gleolan Neurosurgeon Training Program at Gleolan.com/HCP/TRAINING*

Online training program provided by Medexus Pharma, Inc.

*This is not surgical training.

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions (continued)

In a randomized clinical trial, the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to ALA fluorescence arm compared to the control arm. An imbalance was notable for the adverse events aphasia, ataxia, convulsion and hemianopsia and is likely related to the higher amount of brain resection performed in the ALA arm. At longer follow-up periods, the numbers between the two arms appeared similar.

Please see full Important Safety Information on page 7 and full Prescribing Information in pocket.


FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
9 NONCLINICAL TOXICOLOGY
10 OVERDOSAGE
11 DESCRIPTION
11.1 Chemical Properties
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 How Supplied/Storage and Handling
15 CLINICAL TRIALS
15.1 Clinical Trial Experience
16 PATIENT COUNSELING INFORMATION
17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION CONTENTS*

1 INDICATIONS AND USAGE
Gleolan® (aminolevulinic acid hydrochloride) for oral solution Initial U.S. Approval: [1999]

2 DOSAGE AND ADMINISTRATION

- For oral use only (2.1)
- Recommended reconstituted oral dose of Gleolan is 20 mg/kg. (2.1)
- For oral use only (2.1)
- Administer Gleolan to patient orally 3 hours (range 2 to 4 hours) before anesthesia. (2.1)
- See Full Prescribing Information for reconstitution information. (2.2)
- Use appropriate visualisation techniques with appropriate surgical microscopes and light source filters. (2.4)

2 DOSAGE FORMS AND STRENGTHS
For oral solution: 1,500 mg aminolevulinic acid hydrochloride lyophilized powder, equivalent to 1,370 mg aminolevulinic acid per vial. The reconstituted aminolevulinic acid hydrochloride solution contains 30 mg per ml and is clear and colorless to slightly yellowish in color. (3)

2 CONTRAINDICATIONS
- Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. (4, 5.3, 6.2)
- Acute or chronic types of porphyria. (4)

2 ADVERSE REACTIONS
- Phototoxic reactions: Do not administer phototoxic drugs (St. John’s wort, griseofulvin, thiazide diuretics, salicylates, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA during the perioperative period. Red exposure to sunlight or room lights for 48 hours after oral administration of Gleolan. (5.1, 7)
- Risk of misinterpretation: Non-fluorescing tissue in the surgical field does not rule out the presence of tumor. (5.2, 14)

2 PRECAUTIONS

- Calculate the administration volume, in ml, to achieve the intended dose according to the following equation:

\[
\text{Administration Volume (ml)} = \frac{\text{Patient Body Weight (kg) \times 20 mg/kg}}{30 mg/ml}
\]

- Determine the number of vials needed to achieve the intended dose for the patient according to the equation below (rounded up to the nearest whole vial):

\[
\text{# of vials} = \frac{\text{Patient Body Weight (kg)}}{75 \text{ mg/vial}}
\]

- Completely remove the white cap and aluminum crimp seal from each vial.
- Remove and retain the rubber stopper from the vial.
- Using an appropriate volumetric measuring device (e.g., flask, graduated cylinder, dosing syringe), measure 30 ml of drinking water and add to each vial containing 1,500 mg of Gleolan.
- Gently swirl the vial to completely dissolve the powder.
- The resulting reconstituted solution (10 mg of Gleolan per ml) is clear and colorless to slightly yellowish.
- If required, replace the stopper and store reconstituted solution for up to 24 hours at room temperature prior to administration.

2.3 Gleolan Administration

Gleolan is for ORAL USE ONLY. The reconstituted Gleolan solution is administered according to the following steps:

- Transfer the contents of the prepared vial(s) into an appropriate dosing container (e.g., oral medicine bottle); ensure the entire contents of the vials are transferred.
- After transfer, discard the empty vial(s).
- Using a disposable volumetric syringe, remove the administration volume of reconstituted Gleolan solution from the dosing container and transfer to a separate oral dosing container.
- Discard unused volume of Gleolan solution.
- Administer orally 3 hours (range 2 to 4 hours) prior to induction of anesthesia.

2.4 Imaging Instructions

- Gleolan must be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40-80 mW/cm2) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm. Filters transmit porphyrin fluorescence as red-violet, as well as a fraction of backscattered blue excitation light necessary for distinguishing nonfluorescing tissue.
- GEolan should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Training is provided by the distributor.

3 DOSAGE FORMS AND STRENGTHS
For oral solution: 1,500 mg aminolevulinic acid hydrochloride (ALA HCI) lyophilized powder, equivalent to 1,370 mg aminolevulinic acid (ALA), in a 50 ml single-dose clear, colorless, glass vial with rubber stopper. After reconstitution with 50 ml drinking water, the solution contains 30 mg per ml of aminolevulinic acid hydrochloride (equivalent to 23.4 mg per ml of aminolevulinic acid) and is clear and colorless to slightly yellowish in color.

4 CONTRAINDICATIONS
- Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. (5.3)
- Acute or chronic types of porphyria, due to potential ineffectiveness of the drug in these patients.

5 WARNINGS AND PRECAUTIONS

- Risk of Phototoxic Reaction
- Due to the risk of phototoxic reactions, do not administer phototoxic drugs (St. John’s wort, griseofulvin, thiazide diuretics, salicylates, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period (see Drug Interactions [7]). Red exposure to sunlight or room lights for 48 hours after administration of Gleolan.

- Risk of Misinterpretation
- Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma (see Clinical Trials [7]). Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

5.3 Hypersensitivity Reactions
Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria (see Contraindications [4], Adverse Reactions [6.2]). Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

- The safety of Gleolan is supported by data from 5 open label clinical studies, which included 577 patients with glioma who received AHA HCI. Adverse reactions that occurred in > 1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting. Adverse reactions occurring in the first 6 weeks after surgery in < 1% of patients were: chills, phototoxic reactivity, solar dermatitis, hypotension, abnormal liver function test, and diarrhea. One patient experienced respiratory failure due to drug overdose (see Overdosage [10]).

- Neurologic Events
Nervous system disorders occurred in 29% of patients within the first week after surgery. Events occurring in > 1% of patients included aphasia (6%), hemiparesis (7.8%), hemianopsia (13.2%), headache (12.2%), seizure (11.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in < 1% of patients in the first 6 weeks after surgery. In a randomized clinical trial (Study 3), the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to AHA fluorescence arm compared to the control arm. An imbalance was noted for the adverse events aphasias, ataxia, convulsion and hemiparesis, and is likely related to the higher amount of brain resection performed in the AHA arm. At longer follow up periods, the numbers between the two arms appeared similar (see Clinical Trials [14]).

- Elevated Liver Enzymes
Worsening of 2 Common Toxicity Criteria (CTC) grades in alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) occurred in (15.8% and 11.6%, respectively) within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal (ULN) for each parameter. At 6 weeks, ALT remained elevated in 2.9% of patients (range 2 to greater than 5 X ULN), and GGT was elevated in 7.5% of patients (range 2 to greater than 10 X ULN). No cases of liver failure occurred.
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available human data on Gleolan in pregnant women to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral ALA HCI administration to pregnant rabbits during organogenesis at doses 3 times the maximum recommended human oral dose (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Animal data

ALA HCI was administered to rats at oral doses of 15, 50 and 150 mg/kg/day (approximately 0.1, 0.6, and 2 times the maximum human recommended dose [MRHD], respectively based on AUC comparisons) from gestation days 6-18. The no-observed-adverse-effect level (NOEL) for maternal toxicity was 50 mg/kg/day and the NOEL for embryo-fetal developmental toxicity was 150 mg/kg/day.

8.2 Lactation

Risk summary

There are no data on the presence of ALA HCI in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Gleolan and any potential adverse effects on the breastfed infant from Gleolan from the underlying maternal condition.

Clinical Considerations

To decrease exposure to Gleolan to the breastfed infant, advise a lactating woman to pump and discard breast milk after the administration of Gleolan for 24 hours (i.e., 5-6 half-lives).

8.4 Pediatric Use

The safety and effectiveness of Gleolan in pediatric patients have not been established.

8.5 Geriatric Use

Of 527 subjects in clinical studies of Gleolan, 182 were 65 to <75 years of age and 72 were ≥75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. No dose adjustment is required in elderly patients.

8.6 Patients with Renal Impairment

Because approximately one third of the ALA dose is excreted in urine as parent drug, ALA clearance may be reduced in patients with renal impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3)].

8.7 Patients with Hepatic Impairment

The contribution of the liver to the elimination of ALA following Gleolan dosing is unknown. ALA clearance may be reduced in patients with hepatic impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Overdosage has been associated with respiratory insufficiency and erythema. In the event of overdose, supportive measures should be provided as necessary, including protection from strong light sources.

11 DESCRIPTION

11.1 Chemical Properties

Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent for oral use. The 50-mL clear, colorless, glass vial contains 1.500 mg of pyrrolylaminolevulinic acid HC powder (equivalent to 1,770 mg of aminolevulinic acid). After reconstitution, the product has a concentration of 30 mg of aminolevulinic acid hydrochloride per mL (equivalent to 23.4 mg of aminolevulinic acid per mL). The chemical name is 5-amino-6-carboxy-pentacontanoic acid. The chemical formula for aminolevulinic acid hydrochloride is C33H57ClN7O12. Its molecular weight is 673.9 g/mol with the following structural formula:

![Chemical Structure of Aminolevulinic Acid](image)

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of ALA in neoplastic brain tissue is not known.

During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm²) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient Pp IX metabolism appears blue.

12.2 Pharmacodynamics

The effect of the timing of the Gleolan dosing on fluorescence intensity in brain tissue is unknown. The relationship between systemic ALA plasma concentrations at the time of visualization and fluorescence intensity in brain is also unknown. The dose of 20 mg / kg provided stronger ALA-induced fluorescence in glioma tissue by both visual and spectroscopic assessment compared to lower doses tested.

Cardiac Electrochemistry

Adoption of the approved recommended dose of Gleolan did not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

In 12 healthy subjects, the mean half-life of ALA following the recommended dose of Gleolan solution was 0.9 ± 1.2 hours (mean ± std dev) with a range of 0.8 to 1.3 hours. Maximum concentrations of the Pp IX metabolite for Pp IX occurred with a median of 4 hours and a range of 1.2 to 7.8 hours. The elimination half-life of Pp IX was 3.6 ± 1.8 hours (mean ± std dev) with a range of 1.2 to 7.8 hours.

Abnormalities

In 12 healthy subjects, the absolute bioavailability of ALA following the recommended dose of Gleolan solution was 100.0% ± 1.1% with a range of 78.5% to 131.2%. Maximum ALA plasma concentrations were reached with a median of 0.8 hour (range 0.5 – 1.0 hour).

Distribution

In vitro experiments using ALA concentrations up to approximately 25% of the maximal concentration that occurs in plasma following the recommended dose of Gleolan solution, the mean protein binding of ALA was 72%.

Elimination

Metabolism

Exogenous ALA is metabolized to Pp IX, but the fraction of administered ALA that is metabolized to Pp IX is unknown. The average plasma RUC of Pp IX is less than 6% of that of ALA.

Excretion

In 12 healthy subjects, excretion of parent ALA in urine in the 12 hours following administration of the recommended dose of Gleolan solution was 34 ± 8% (mean ± std dev) with a range of 27% to 57%.

Specific Populations

The effect of renal or hepatic impairment on the pharmacokinetics of ALA following Gleolan administration is unknown.

Drug Interaction Studies

In vitro studies suggest that phenytoin and other anti-convulsants may decrease cellular Pp IX accumulation following Gleolan dosing.

ALA is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenicity studies have been conducted with Gleolan.

Mutagenesis

ALA HCI was not mutagenic in the Ames assay, Hprt-V79 mammalian cell mutagenicity test, the peripheral human lymphocyte chromosomal aberration assay and the in vivo mouse micronucleus test when studies were performed in the dark or under subdued lighting.

Impairment of fertility

No fertility studies have been conducted with Gleolan.

14 CLINICAL STUDIES

The efficacy of 20 mg / kg ALA HCI was evaluated in 3 clinical studies (Study 1-3) involving patients, ages 18 to 75 years old, who had a presurgical MRI compatible with high-grade glioma (WHO Grade III or IV) and were undergoing surgical resection.

Study 1 was an open-label study of 13 patients with newly diagnosed high-grade glioma and Study 2 was an open-label study of 36 patients with recurrent high-grade glioma. In Studies 1 and 2, after initial debulking was carried out under white light, biopsy were obtained under fluorescent light from fluorescent and nonfluorescent sites. Presence of fluorescence (positive/negative) was compared to tumor status (true/false) using histopathology as the reference standard. True positives and false positives among fluorescent biopsies and true negatives and false negatives among nonfluorescent biopsies are provided in Table 1.

Study 3 was a randomized, multicenter study in 415 patients with a prespecified diagnosis of high-grade glioma by MRI. Patients were randomized in a 1:1 ratio to ALA fluorescence arm or to white light control arm. Biopsies were obtained from tumor-core, tumor-margin and regions just distant to the tumor margins. In 349 patients high grade glioma was confirmed by a blinded central read and histopathology. The remaining patients were diagnosed with metastatic disease, abscess, low-grade glioma or other conditions.

In patients with confirmed high-grade glioma randomized to the ALA fluorescence arm, presence of fluorescence at a biopsy level was compared to tumor status using histopathology as the reference standard (Table 1). In 4 patients with low-grade glioma (WHO Grade I or II) who received ALA HCI, 9 out of 10 biopsies were false negative.

The extent of resection among patients with confirmed high-grade glioma in the ALA fluorescence arm was compared to that among patient in the control arm, with the ‘completeness’ of resection being determined by a central blinded read of early post-surgical MRI. Percentage of patients who had ‘completeness’ of resection was 64% in the ALA arm and 38% in the control arm, with the difference of 26% [95% CI: (16%, 36%)].

18 HOW SUPPLIED/STORAGE AND HANDLING

18.1 How Supplied

Gleolan (NDC 59137-231-01) is supplied as 1,500 mg of pyrrolylaminolevulinic acid hydrochloride powder (equivalent to 1,770 mg of aminolevulinic acid), for oral solution in a 50-mL clear, colorless, glass vial with a rubber stopper and an aluminum/stamp seal.

18.2 Storage and Handling

Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F).

17 PATIENT COUNSELING INFORMATION

Advise patients that they may experience elevated liver enzymes (ALT and GGT) within the first week after surgery. This elevation may persist for 6 weeks. Advise patients to reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan due to risk of phototoxic reactions.

Manufactured by: Medexus Pharma, Inc.
Chicago, IL 60605
Product of Germany

Table 1. Presence of Fluorescence Compared to Histopathology (biopsy level)

<table>
<thead>
<tr>
<th>Study</th>
<th>fluorescence biopsy</th>
<th>True positive</th>
<th>False positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>185</td>
<td>178</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>334</td>
<td>342</td>
<td>30</td>
</tr>
<tr>
<td>3</td>
<td>319</td>
<td>312</td>
<td>7</td>
</tr>
</tbody>
</table>

* N is Number of total (fluorescent and non-fluorescent) biopsies